Business Context and Reporting Period
This Form 8-K Current Report was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on April 19, 2024. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on the status of the Company's stock listing.
Material Changes and Listing Status
- Trigger Event: The Company's common stock closed below the $1.00 per share minimum bid price requirement for 30 consecutive business days.
- Regulatory Action: Nasdaq issued a notice of failure to satisfy the Bid Price Requirement under Listing Rule 5450(a)(1).
- Current Status: The stock continues to trade on the Nasdaq Global Select Market under the symbol "MCRB" pending compliance.
- Compliance Deadline: The Company has an initial 180-day compliance period ending on October 16, 2024.
- Compliance Criteria: To regain compliance, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days prior to the deadline.
Outlook, Risks, and Management Commentary
Management intends to monitor the stock price and may consider actions to regain compliance, including a reverse stock split, subject to Board and stockholder approval. The filing explicitly states there is no assurance that the Company will regain compliance, successfully implement a reverse split, or that an appeal would be successful if a delisting determination is made.
If the Company fails to regain compliance by October 16, 2024, it may be eligible for an additional 180-day period to transfer its listing to The Nasdaq Capital Market, provided it meets specific market value and listing standards for that tier. Failure to cure the deficiency within applicable periods could result in delisting.
Investor Verification Checklist
- Verify the current closing bid price of MCRB to assess proximity to the $1.00 threshold.
- Monitor Company announcements regarding the potential implementation of a reverse stock split.
- Review the Company's 2024 Form 10-K for detailed risk factors and financial health context not included in this 8-K.
- Track the 180-day compliance timeline ending October 16, 2024.